Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Depreciation & Amortization (CF) (2016 - 2025)

Protalix BioTherapeutics (PLX) has 16 years of Depreciation & Amortization (CF) data on record, last reported at $372000.0 in Q3 2025.

  • For Q3 2025, Depreciation & Amortization (CF) rose 13.07% year-over-year to $372000.0; the TTM value through Sep 2025 reached $1.4 million, up 10.05%, while the annual FY2024 figure was $1.3 million, 9.49% up from the prior year.
  • Depreciation & Amortization (CF) reached $372000.0 in Q3 2025 per PLX's latest filing, up from $360000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $372000.0 in Q3 2025 and bottomed at $259000.0 in Q4 2021.
  • Average Depreciation & Amortization (CF) over 5 years is $304052.6, with a median of $293000.0 recorded in 2023.
  • Peak YoY movement for Depreciation & Amortization (CF): fell 23.94% in 2021, then rose 15.0% in 2024.
  • A 5-year view of Depreciation & Amortization (CF) shows it stood at $259000.0 in 2021, then increased by 6.18% to $275000.0 in 2022, then rose by 13.82% to $313000.0 in 2023, then grew by 6.71% to $334000.0 in 2024, then rose by 11.38% to $372000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Depreciation & Amortization (CF) were $372000.0 in Q3 2025, $360000.0 in Q2 2025, and $346000.0 in Q1 2025.